UY26145A1 - METALOPROTEASE INHIBITOR AROMATIC SULFOHIDROXAMIC ACID LAW 17164 ART 127 - Google Patents
METALOPROTEASE INHIBITOR AROMATIC SULFOHIDROXAMIC ACID LAW 17164 ART 127Info
- Publication number
- UY26145A1 UY26145A1 UY26145A UY26145A UY26145A1 UY 26145 A1 UY26145 A1 UY 26145A1 UY 26145 A UY26145 A UY 26145A UY 26145 A UY26145 A UY 26145A UY 26145 A1 UY26145 A1 UY 26145A1
- Authority
- UY
- Uruguay
- Prior art keywords
- mmp
- sulfohidroxamic
- metaloprotease
- inhibitor
- art
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000005741 Metalloproteases Human genes 0.000 abstract 2
- 108010006035 Metalloproteases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 abstract 1
- 102100027995 Collagenase 3 Human genes 0.000 abstract 1
- 108050005238 Collagenase 3 Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 abstract 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe un proceso de tratamiento, el cual comprende la administración a un huésped que presenta una condición asociada con actividad patológica de la metaloproteasa matriz de una cantidad efectiva de un ácido sulfon-hidroxámico aromático que presenta una excelente actividad inhibitoria de una o más de las encimas de la metaloproteasa matriz (MMP), tales como MMP-2, MMP-9 y MMP-13, mientras que presenta una actividad inhibitoria sustancialmente menor al menos contra la MMP-1. También se describen compuestos inhibidores de la metaloproteasa que tienen esas actividades selectivas, procesos para la elaboración de dichos compuestos y composiciones farmacéuticas que utilizan un inhibidor.A treatment process is described, which comprises the administration to a host that presents a condition associated with pathological activity of the matrix metalloprotease of an effective amount of an aromatic sulfon-hydroxamic acid that has an excellent inhibitory activity of one or more of the matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against at least MMP-1. Also described are metalloprotease inhibitor compounds that have these selective activities, processes for the elaboration of said compounds and pharmaceutical compositions that use an inhibitor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31183799A | 1999-05-14 | 1999-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY26145A1 true UY26145A1 (en) | 2000-12-29 |
Family
ID=27757522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY26145A UY26145A1 (en) | 1999-05-14 | 2000-05-15 | METALOPROTEASE INHIBITOR AROMATIC SULFOHIDROXAMIC ACID LAW 17164 ART 127 |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR035547A1 (en) |
| CO (1) | CO5251417A1 (en) |
| PE (1) | PE20010202A1 (en) |
| UY (1) | UY26145A1 (en) |
| ZA (1) | ZA200109006B (en) |
-
2000
- 2000-05-15 CO CO00035030A patent/CO5251417A1/en not_active Application Discontinuation
- 2000-05-15 AR ARP000102342 patent/AR035547A1/en not_active Application Discontinuation
- 2000-05-15 PE PE2000000455A patent/PE20010202A1/en not_active Application Discontinuation
- 2000-05-15 UY UY26145A patent/UY26145A1/en not_active Application Discontinuation
-
2001
- 2001-10-31 ZA ZA200109006A patent/ZA200109006B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20010202A1 (en) | 2001-02-19 |
| ZA200109006B (en) | 2002-12-02 |
| AR035547A1 (en) | 2004-06-16 |
| CO5251417A1 (en) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU79901A (en) | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | |
| EA200100804A1 (en) | SULPHOOROMATIC DERIVATIVES OF HYDROXAMIC ACID AS METHYPE PROTEASIS INHIBITORS | |
| Jiang et al. | Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice | |
| BR0008440A (en) | Hydroxamic acid sulfamate metalloprotease inhibitor | |
| EA201001523A1 (en) | MATRIX METALLOPROTEASE INHIBITORS BASED ON ARYLSULPHONAMIDE | |
| EP1562897A4 (en) | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| ATE277929T1 (en) | IMMUNOSUPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | |
| BR9713186A (en) | 1,3-diheterocyclic metalloprotease inhibitors | |
| NO20074647L (en) | 3,4 dihydro-1H-isoquinoline-2-carboxylic acid 5-ammopyridin-2-yl esters | |
| WO2004017920A3 (en) | Novel biphenyl and biphenyl-like cannabinoids | |
| DK1317419T3 (en) | Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents | |
| BR0109353A (en) | Heterocyclic Side Chain Containing Metalloprotease Inhibitors | |
| BRPI0516132A (en) | compounds, composition thereof, method of antagonizing one or more aspartic proteases and method for treating or ameliorating an aspartic protease-mediated disorder | |
| KR950031059A (en) | Pharmaceutical composition for the treatment of osteoporosis | |
| DK1296972T3 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
| NZ526913A (en) | Inhibitors of cruzipain and other cysteine proteases | |
| EP1208092A4 (en) | SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR | |
| WO2002034201A3 (en) | Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy | |
| HUP9802971A1 (en) | The use of mmp inhibitors for the treatments of ocular angiogenesis | |
| NO983991L (en) | Serine protease inhibitors | |
| NZ515197A (en) | Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors | |
| WO2005117882A8 (en) | Hydroxamic acid derivatives as metalloprotease inhibitors | |
| EA199900057A1 (en) | MATRIX METALLOPROTEINASE INHIBITORS | |
| WO2001091796A8 (en) | Methods, compounds and compositions for treating gout | |
| BR0109348A (en) | Unsubstituted metalloprotease inhibitors which contain carbocyclic side chains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20100426 |